The Implications of Recent Datasets for the Current and Future Management of Gynecologic Cancers — An ASCO 2026 Review

Wednesday, August 26, 2026
5:00 PM – 6:00 PM ET
Live CME/MOC-accredited webinar

Topics to Be Discussed

• Ovarian Cancer
• Endometrial Cancer
• Cervical Cancer

Target Audience
This activity is intended for gynecologic oncologists, medical oncologists, gynecologists and other healthcare providers involved in the diagnosis and treatment of gynecologic cancers.

Learning Objectives
Upon completion of this activity, participants should be able to

• Understand available clinical research findings with PARP inhibitors as maintenance therapy after first-line platinum-based chemotherapy for patients with advanced ovarian cancer (OC), and as appropriate, provide counsel regarding personalized treatment recommendations.
• Recognize the rationale for targeting folate receptor alpha (FRα) in OC, and understand the mechanism of action of and available research findings with FRα-directed antibody-drug conjugates (ADCs).
• Appreciate available research findings with anti-PD-1/PD-L1 antibodies in combination with chemotherapy for patients with platinum-resistant OC, and consider the role of this novel therapeutic strategy in clinical practice.
• Understand the biological justification for the evaluation of selective glucocorticoid receptor modulators in combination with chemotherapy for patients with platinum-resistant OC, and recall available Phase III findings with this novel approach.
• Assess the incidence of cadherin-6 expression in OC, and understand the available data with and structural components and mechanism of action of novel ADCs directed at this target.
• Appreciate available clinical research findings with anti-PD-1/PD-L1 antibodies in combination with chemotherapy as first-line treatment for advanced or recurrent endometrial cancer (EC), and optimally incorporate this novel strategy into the care of patients with microsatellite instability-high/mismatch repair-deficient and microsatellite stable/mismatch repair-proficient disease.
• Appraise biological and patient- and treatment-related factors to individualize the selection and sequencing of therapy for cervical cancer (CC).
• Evaluate published clinical research documenting the efficacy of HER2-targeted agents and regimens for HER2-overexpressing EC, OC and CC, and consider the role of various approaches in the care of patients with these diseases.
• Recognize the biological rationale for the evaluation of TROP2-directed ADCs for patients with OC, EC and CC, and consider available research findings with and potential role of these agents.
• Describe the scientific justification for, published data with and current research studies of novel agents and strategies for OC, EC and CC, and effectively prioritize clinical trial opportunities for eligible patients.

CE Credit
CME and ABIM MOC credit information will be provided to each participant at the conclusion of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC) 
Successful completion of this CME activity, which includes participation in the evaluation component and a post-test, enables the participant to earn up to 1 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for this activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. 

Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.

American Board of Surgery (ABS) — Continuous Certification (CC)
Successful completion of this CME activity, which includes participation in the evaluation component and a post-test, enables the learner to earn up to 1 Medical Knowledge MOC point toward the CME and Self-Assessment requirement(s) of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABS credit.

Please note, this program has been specifically designed for the following ABS practice area: complex general surgical oncology. 

Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

Unlabeled/Unapproved Uses Notice
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the provider or grantors.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. 

FACULTY
Dr Konecny has no relevant financial relationships to disclose. The following faculty reported relevant financial relationships:

Dr Slomovitz — Consulting Agreements: Aadi Bioscience, AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeOne, BioNTech SE, Corcept Therapeutics Inc, Daiichi Sankyo Inc, Eisai Inc, Genmab US Inc, GSK, Incyte Corporation, Karyopharm Therapeutics, Merck; Data and Safety Monitoring Boards/Committees: Genelux Corporation.

MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Agendia Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeOne, Biotheranostics Inc, A Hologic Company, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Catalyst Pharmaceuticals Inc, Celcuity, Clovis Oncology, Coherus BioSciences, Corcept Therapeutics Inc, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Helsinn Therapeutics (US) Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Nuvation Bio Inc, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Revolution Medicines Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Pharma America, Summit Therapeutics, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, and Verastem Inc. 

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

Supporters
This activity is supported by educational grants from Corcept Therapeutics Inc and GSK.

Please click the link to register for this live event directly on Zoom. Once you register, Zoom will send a confirmation email with your individual link to access the event. Please keep that confirmation email handy. If you do not receive it, contact our support team at meetings@researchtopractice.com.